Lysophosphatidic Acid Receptor 1 (LPA 1 ) Antagonists as Potential Migrastatics for Triple Negative Breast Cancer
ChemMedChem · 2024
DOI: 10.1002/cmdc.202400013 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, 2024. Verfasst von Wenjie Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Lakehead University, 955 Oliver Rd, Thunder Bay, ON, P7B 5E1, Canada. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Receptors, Lysophosphatidic Acid, Antineoplastic Agents, Cell Movement. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Natural Sciences and Engineering Research Council of Canada (NSERC), Canada Foundation for Innovation (CFI), Ontario Research Fund (ORF).
Abstract (Originalsprache)
Metastasis is responsible for about 90 % of cancer deaths. Anti‐metastatic drugs, termed as migrastatics, offer a distinctive therapeutic approach to address cancer migration and invasion. However, therapeutic exploitation of metastasis‐specific targets remains limited, and the effective prevention and suppression of metastatic cancer continue to be elusive. Lysophosphatidic acid receptor 1 (LPA 1 ) is activated by an endogenous lipid molecule LPA, leading to a diverse array of cellular activities. Previous studies have shown that the LPA/LPA 1 axis supports the progression of metastasis for many types of cancer. In this study, we report the synthesis and biological evaluation of fluorine‐containing triazole derivatives as potent LPA 1 antagonists, offering potential as migrastatic drugs for triple negative breast cancer (TNBC). In particular, compound 12 f , the most potent and highly selective in this series with an IC 50 value of 16.0 nM in the cAMP assay and 18.4 nM in the calcium mobilization assay, inhibited cell survival, migration, and invasion in the TNBC cell line. Interestingly, the compound did not induce apoptosis in TNBC cells and demonstrated no cytotoxic effects. These results highlight the potential of LPA 1 as a migrastatic target. Consequently, the LPA 1 antagonists developed in this study hold promise as potential migrastatic candidates for TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Lakehead University, 955 Oliver Rd, Thunder Bay, ON, P7B 5E1, Canada.
- Thunder Bay Regional Health Research Institute, 980 Oliver Road, Thunder Bay, ON, P7B 6 V4, Canada.
- Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Canada.
- Keenan Research Centre for Biomedical Science at St. Michael's Hospital, Toronto, Ontario, Canada.
- Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
- Northern Ontario School of Medicine University, Thunder Bay, Ontario, Canada.
ORCID-Profile: Jinqiang Hou
Förderung
- Natural Sciences and Engineering Research Council of Canada (NSERC)
- Canada Foundation for Innovation (CFI)
- Ontario Research Fund (ORF)
- Thunder Bay Regional Health Research Institute
- Lakehead University
Zitieren
APA
Liu, W., Mousa, A. A. K., Hopkins, A. M., Wu, Y. F., Thu, K. L., Campbell, M., Lees, S. J., Ramachandran, R., & Hou, J. (2024). Lysophosphatidic Acid Receptor 1 (LPA 1 ) Antagonists as Potential Migrastatics for Triple Negative Breast Cancer. ChemMedChem. https://doi.org/10.1002/cmdc.202400013
Vancouver
Liu W, Mousa AAK, Hopkins AM, Wu YF, Thu KL, Campbell M, et al. Lysophosphatidic Acid Receptor 1 (LPA 1 ) Antagonists as Potential Migrastatics for Triple Negative Breast Cancer. ChemMedChem. 2024. doi:10.1002/cmdc.202400013
BibTeX
@article{Liu2024,
author = {Liu, Wenjie and Mousa, Amr A K and Hopkins, Austin M and Wu, Yin Fang and Thu, Kelsie L and Campbell, Michael and Lees, Simon J and Ramachandran, Rithwik and Hou, Jinqiang},
title = {Lysophosphatidic Acid Receptor 1 (LPA 1 ) Antagonists as Potential Migrastatics for Triple Negative Breast Cancer},
journal = {ChemMedChem},
year = {2024},
doi = {10.1002/cmdc.202400013}
}
EUVIMED